Excerpt:LENVIMA is a kinase inhibitor that is indicated...In combination with everolimus, for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior antiangiogenic therapy.
Title:
lenvatinib (Kisplyx) is accepted for use within NHSScotland
Excerpt:lenvatinib (Kisplyx) is accepted for use within NHSScotland...in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.
Excerpt:In combination with everolimus for the treatment of unresectable advanced or metastatic renal cell carcinoma.
Evidence Level:Sensitive: A2 - Guideline
Excerpt:Lenvatinib plus everolimus is listed as a category 1, other recommended, subsequent therapy by NCCN Kidney Cancer Panel.
Evidence Level:Sensitive: B - Late Trials
Title:
Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).
Excerpt:...LEN + EVE (median 15 mos) vs SUN (HR 0.65, 95% CI 0.53–0.80)….LEN + EVE (ORR 54%; CR 10%) vs SUN (odds ratio 2.15, 95% CI 1.57–2.93)...LEN + EVE demonstrated significant improvements in PFS and ORR vs SUN.
DOI:10.1200/JCO.2021.39.6
Evidence Level:Sensitive: B - Late Trials
New
Title:
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrated Statistically Significant Improvement in Progression-Free Survival (PFS), Overall Survival (OS) and Objective Response Rate (ORR) Versus Sunitinib as First-Line Treatment for Patients…
Excerpt:LENVIMA plus everolimus also met the trial’s primary endpoint of PFS and a key secondary endpoint of ORR, demonstrating a statistically significant and clinically meaningful improvement in PFS and ORR versus sunitinib in the ITT study population.
Evidence Level:Sensitive: B - Late Trials
Title:
Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) + everolimus (EVE) versus sunitinib (SUN) treatment arms.
Excerpt:...pts in the LEN + EVE arm had a longer median time from randomization to initiation of subsequent therapy vs those in the SUN arm (8.0 vs 6.6 months, respectively)....LEN + EVE met the primary endpoint of a significant benefit in PFS vs SUN.
DOI:10.1200/JCO.2021.39.15_suppl.4562